文献速递银屑病与炎症性皮肤病

接受古塞奇尤单抗或阿达木单抗治疗的中重度银屑病患者报告的症状和体征:随机VOYAGE 1试验结果

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-04-10

VOYAGE 1试验中,中重度银屑病患者随机接受古塞奇尤单抗100 mg每8周、安慰剂转古塞奇尤单抗100 mg每8周或阿达木单抗40 mg每2周治疗,采用银屑病症状和体征日记(PSSD)评估。第16周时古塞奇尤单抗组PSSD汇总评分达到临床意义改善的比例显著高于安慰剂组(P<0.001),第24周(P=0.002)和第48周(P<0.001)显著高于阿达木单抗组。

要点

  • 古塞奇尤单抗组第16周PSSD汇总评分临床意义改善比例显著高于安慰剂组(P<0.001)。
  • 古塞奇尤单抗组第24周和第48周PSSD汇总评分临床意义改善比例显著高于阿达木单抗组(P=0.002和P<0.001)。
  • 古塞奇尤单抗组第16周及第24、48周PSSD症状和体征汇总评分为0的比例均显著更高(均P<0.001)。

核心结论

  • 基于PSSD评分,古塞奇尤单抗治疗的患者报告的症状和体征改善程度在第16周优于安慰剂,在48周内优于阿达木单抗。

研究设计与样本

  • VOYAGE 1是一项正在进行的III期双盲对照试验,纳入中重度银屑病患者。
  • 患者随机接受古塞奇尤单抗100 mg每8周、安慰剂转古塞奇尤单抗100 mg每8周或阿达木单抗40 mg每2周治疗。
  • PSSD由患者每24小时自行填写,评估瘙痒、皮肤紧绷、灼烧、刺痛和疼痛等症状以及干燥、皲裂、脱屑、脱落/鳞屑、发红和出血等体征(0-10分,0为无,10为最严重)。
  • 症状和体征汇总评分基于各单项平均分得出(0-100分)。
  • 在第16、24和48周评估各治疗组达到临床意义改善以及症状和体征汇总评分为0的患者比例。

主要发现

  • 基线时,837例随机患者中有652例有PSSD评分。
  • 第16周时,古塞奇尤单抗组达到PSSD汇总评分临床意义改善的患者比例显著高于安慰剂组(P<0.001)。
  • 第24周(P=0.002)和第48周(P<0.001)时,古塞奇尤单抗组达到PSSD汇总评分临床意义改善的患者比例显著高于阿达木单抗组。
  • 第16周时古塞奇尤单抗组达到PSSD症状和体征汇总评分为0(即无症状和体征)的患者比例显著高于安慰剂组(均P<0.001)。
  • 第24周和第48周时古塞奇尤单抗组达到PSSD症状和体征汇总评分为0的患者比例显著高于阿达木单抗组(均P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: How patients experience the symptoms/signs of psoriasis is highly relevant for assessing treatment response. OBJECTIVES: Compare outcomes with guselkumab, placebo and adalimumab utilizing the novel, validated Psoriasis Symptoms and Signs Diary (PSSD). METHODS: VOYAGE 1 is an ongoing, phase III, double-blinded, controlled trial of patients with moderate-to-severe psoriasis. Patients were randomized to guselkumab 100 mg every 8 weeks; placebo-to-guselkumab 100 mg every 8 weeks; or adalimumab 40 mg every 2 weeks. The PSSD was self-administered to assess symptoms (i.e. itch, skin tightness, burning, stinging and pain) and signs (i.e. dryness, cracking, scaling, shedding/flaking, redness and bleeding) of psoriasis (0-10 [absent-to-worst-imaginable]) every 24 h. Symptom and sign summary scores were derived (0-100) based on average scores of the individual symptoms and signs. Proportions of patients with clinically meaningful improvements and symptom- and sign-free scores of 0 were evaluated across treatment groups at weeks 16, 24 and 48. RESULTS: At baseline, 652 of 837 randomized patients had PSSD scores. The proportion of patients achieving clinically meaningful improvements in PSSD summary scores was significantly higher in the guselkumab group compared with the placebo group at week 16 (P < 0.001) and compared with the adalimumab group at weeks 24 (P = 0.002) and 48 (P < 0.001). The proportions of patients achieving PSSD symptom and sign summary scores of 0 (i.e. symptom- and sign-free) were significantly higher for guselkumab vs. placebo at week 16 and vs. adalimumab at weeks 24 and 48 (all P < 0.001). CONCLUSIONS: Based on PSSD scores, greater improvements in symptoms and signs of psoriasis were reported by patients treated with guselkumab compared with placebo at week 16 or adalimumab through 48 weeks.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Papp KA, Blauvelt A, Kimball AB, et al. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. J Eur Acad Dermatol Venereol. 2018. PMID: 29512196. doi:10.1111/jdv.14910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。